Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.

Watcharee RungapiromnanK J MasonM LuntK McElhoneA D BurdenM K RutterR B WarrenC E M GriffithsD M Ashcroftnull null

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2019)

In this large prospective cohort study, we found no significant differences in the risk of major CVEs between three different biologic therapies and methotrexate. Additional studies, with longer term follow-up, are needed to investigate the potential effects of biologic therapies on incidence of major CVEs.

Keyphrases

cardiovascular events
rheumatoid arthritis
coronary artery disease
cardiovascular disease
risk factors
preterm infants
high dose
low dose
climate change
gestational age
human health